Abstract
Doxorubicin (DOX) is a widely used chemotherapeutic anticancer drug. Its intrinsic fluorescence properties enable investigation of tumor response, drug distribution and metabolism. First phantom studies in vitro showed optoacoustic property of DOX. We therefore aimed to further investigate the optoacoustic properties of DOX in biological tissue in order to explore its potential as theranostic agent. We analysed doxorubicin hydrochloride (Dox·HCl) and liposomal encapsulated doxorubicin hydrochloride (Dox·Lipo), two common drugs for anti-cancer treatment in clinical medicine. Optoacoustic measurements revealed a strong signal of both doxorubicin substrates at 488 nm excitation wavelength. Post mortem analysis of intra-tumoral injections of DOX revealed a detectable optoacoustic signal even at three days after the injection. We thereby demonstrate the general feasibility of doxorubicin detection in biological tissue by means of optoacoustic tomography, which could be applied for high resolution imaging at mesoscopic depths dictated by effective penetration of visible light into the biological tissues.
Highlights
Doxorubicin hydrochloride, an anthracycline antibiotic, is one of the most commonly used anti-cancer therapeutics
We investigated the optoacoustic properties of both formulations first in vitro. 1 mM of doxorubicin hydrochloride (Dox HCl) and 1 mM of Dox Lipo were measured in an optoacoustic set up
We verified the excitation profile of Dox HCl (Fig 1B) which was in agreement with the literature
Summary
Doxorubicin hydrochloride, an anthracycline antibiotic, is one of the most commonly used anti-cancer therapeutics. The generation of reactive oxygen species leads to mitochondrial dysfunction, which, as a main side effect causes cardiotoxicity.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
